key: cord-0843162-fmma2g78
authors: Babel, Nina; Anft, Moritz; Blazquez‐Navarro, Arturo; Doevelaar, Adrian A.N.; Seibert, Felix S.; Bauer, Frederic; Rohn, Benjamin J.; Hoelzer, Bodo; Thieme, Constantin J.; Roch, Toralf; Meister, Toni L.; Pfaender, Stephanie; Steinmann, Eike; Dittmer, Ulf; Schenker, Peter; Amann, Kerstin; Viebahn, Richard; Stervbo, Ulrik; Westhoff, Timm H.
title: Immune monitoring facilitates the clinical decision in multifocal COVID‐19 of a pancreas‐kidney transplant patient
date: 2020-08-10
journal: Am J Transplant
DOI: 10.1111/ajt.16252
sha: 4ca201161e28c3e79647c201da55da49ee0a3561
doc_id: 843162
cord_uid: fmma2g78

The optimal management in transplant recipients with COVID‐19 remains uncertain. The main concern is the ability of immunosuppressed patients to generate sufficient immunity for antiviral protection. Here, we report on immune monitoring facilitating a successful outcome of severe SARS‐CoV‐2‐associated pneumonia, meningoencephalitis, gastroenteritis and acute kidney and pancreas graft failure in a pancreas‐kidney transplant recipient. Despite the very low numbers of circulating B‐, NK‐, and T‐cells identified in follow up, a strong SARS‐CoV‐2 reactive T‐cell response was observed. Importantly, we detected T‐cells reactive to Spike, Membrane, and Nucleocapsid proteins of SARS‐CoV‐2 with majority of T‐cells showing polyfunctional pro‐inflammatory Th1 phenotype at all analyzed time points. Antibodies against Spike protein were also detected with increasing titers in follow up. Neutralization tests confirmed their antiviral protection. A correlation between cellular and humoral immunity was observed underscoring the specificity of demonstrated data. We conclude that analyzing the kinetics of non‐specific and SARS‐CoV‐2‐reactive cellular and humoral immunity can facilitate the clinical decision on immunosuppression adjustment and allow successful outcome as demonstrated in the current clinical case. While the antiviral protection of the detected SARS‐CoV‐2‐reactive T‐cells requires further evaluation, our data prove an ability mounting a strong SARS‐CoV‐2‐reactive T‐cell response with functional capacity in immunosuppressed patients.

This article is protected by copyright. All rights reserved

The crucial role of cellular immunity for the antiviral protection is well known, and an association between T-cell immunity and viral clearance has been shown previously by our and other groups (1, 2) . Due to immunosuppressive treatment required to prevent organ rejection, transplant patients are known to be at high risk of viral infections. In fact, enabling an immune response, capable of controlling viral infections under concomitant immunosuppression, is an important challenge in transplant medicine.

Here, we present in-depth monitoring of the general immune status and the analysis of SARS-CoV-2 reactive T-cell and humoral immunity in clinical follow up of a combined pancreas-kidney transplant patient accompanying successful outcome of severe COVID-19. We have very recently provided an in-depth description of his clinical course (Westhoff et al., AJT, in press). The maintenance triple immunosuppressive medication included tacrolimus (Tac) (trough level 4.6 mg/mL), mycophenolic acid (MPA) and prednisolone. Initially, the patient showed symptoms of COVID-19 pneumonia and gastroenteritis and was treated outside of our transplant center. The first positive SARS-CoV-2 PCR was obtained 10 days after the first symptoms. Due to the very high level of tacrolimus (40 mg/mL) caused by severe diarrhea, tacrolimus medication was paused. 21 days after the onset of the first symptoms, the patient suffered a gradual decrease of renal and pancreas graft function and was transferred to our transplant center. At this time point (V1, Figure 1 ) the maintenance immunosuppressive medication was replaced by intravenous hydrocortisone (200 mg/day) due to prolonged convalescence and progressive COVID-19 pneumonia observed in computed tomography, and immune monitoring was initiated. Because of a modest increase in creatinine levels and proteinuria at V1, kidney allograft biopsy was performed to rule out acute allograft rejection. The histopathological findings ruled out acute renal allograft rejection, but moderate interstitial mononuclear cell infiltrate and tubular damage as well as SARS-CoV-2 RNA transcripts were detected by RT-PCR and in-situ hybridization 

COVID-19 is a challenging problem for the health care worldwide. Patients suffering from hypertension, atherosclerotic diseases, diabetes and malignancy are usually at a higher risk for developing a severe disease (3) . For allograft transplant patients, not only the high rate of these co-morbidities and frequent contact with medical care, but also -and especiallyimmunosuppressive therapy can contribute to disease severity. Thus, a crucial role of T-cell immunity for the viral clearance and vaccination response has been shown in previous studies (4) (5) (6) . Due to immunosuppression, the quantity and the functionality of antiviral immunity can be impaired, whereas the impact of different immunosuppressive drugs can vary (5) . The role of SARS-CoV-2-reactive cellular immunity for COVID-19 evolution is not understood. Based on the

This article is protected by copyright. All rights reserved data of the closely related MERS corona virus (7) 

This article is protected by copyright. All rights reserved for the SARS-CoV-2 clearance as shown by our and other groups for other viruses is also not clear (14) . Only few data on SARS-CoV-2 reactive T-cells have been published so far in of nonimmunosuppressed patient cohorts (15) (16) (17) (18) (19) . Data on SARS-CoV-2 reactive cellular immunity in immunosuppressive patients are lacking.

Here, we present data on in-depth monitoring of cellular and humoral immunity in a kidney 

This article is protected by copyright. All rights reserved be observed despite the preexisting immunosuppression. While analysis of circulating T cell subsets with activated memory phenotype provided information on general immune activation level, analysis of SARS-CoV-2 reactive cellular and humoral immunity enabled specific information on antiviral response. Combined monitoring of both arms of immunity facilitated clinical decision making, allowing risk-adjusted guidance of immunosuppressive regimen and successful outcome of severe life-threating COVID-19 complications.

Peripheral blood mononuclear cells (PBMCs) were prepared from whole blood by gradient centrifugation and frozen as recently described (18) . Defrosted PBMCs were stimulated with 1 µg/mL SARS-CoV-2 overlapping peptide pools (Miltenyi Biotec V1-V4, or JPT V5) containing 15mer peptides from S, N, and M protein, respectively, for 16h. Brefeldin A (1µg/ml, Sigma Aldrich) was added after 2h. Immune phenotyping was performed using EDTA treated whole blood. All samples were stained with antibodies directed against the indicated molecules and immediately acquired on a CytoFlex flow cytometer (Beckman Coulter). SARS-CoV-2 IgG titers were analyzed using a commercially available kit (EUROIMMUN) per manufacturer's instructions. Association between the frequency S-protein specific CD4 + T cells, defined by expression of CD154 + , and S1 specific IgG expressed as the ratio of sample to calibrator. 

From vaccines to memory and back

BK polyomavirus infection and nephropathy: the virusimmune system interplay

SARS Cov-2 infection in a renal-transplanted patient: A case report

BKV Clearance Time Correlates With Exhaustion State and T-Cell Receptor Repertoire Shape of BKV-Specific T-Cells in Renal Transplant Patients

A revised strategy for monitoring BKV-specific cellular immunity in kidney transplant patients

Repertoire Analysis by Next Generation Sequencing Allows Complex Differential Diagnosis of T Cell-Related Pathology

Immune Responses to Middle East Respiratory Syndrome Coronavirus During the Acute and Convalescent Phases of Human Infection

Covid-19 and Kidney Transplantation

COVID-19 in solid organ transplant recipients: Initial report from the US epicenter

Renal Transplant Recipients: A Review of Recent Literature and Case Supporting Corticosteroidsparing Immunosuppression

COVID-19 infection in kidney transplant recipients

COVID-19: immunopathology and its implications for therapy

Identification of Kidney Transplant Recipients with Coronavirus Disease

The role of CD4+ T cells in BKV-specific T cell immunity

Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

reactive T cells in COVID-19 patients and healthy donors

A possible role of immunopathogenesis in COVID-19 progression

The TreaT-Assay: A Novel Urine-Derived Donor Kidney Cell-Based Assay for Prediction of Kidney Transplantation Outcome

Profiles of Antibody Responses against Severe Acute Respiratory Syndrome Coronavirus Recombinant Proteins and Their Potential Use as Diagnostic Markers